Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Molecular Cancer
Pignochino, Ymera Y; Grignani, Giovanni G; Cavalloni, Giuliana G; Motta, Manuela M; Tapparo, Marta M; Bruno, Stefania S; Bottos, Alessia A; Gammaitoni, Loretta L; Migliardi, Giorgia G; Camussi, Giovanni G; Alberghini, Marco M; Torchio, Bruno B; Ferrari, Stefano S; Bussolino, Federico F; Fagioli, Franca F; Picci, Piero P; Aglietta, Massimo M